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Indirect excess morbidity in the COVID-19 pandemic may arise from public health risk-
mitigation efforts such as stay-at-home orders and re-purposing of healthcare 
services1. Increased mental health disorders and shortfalls in the care of long-term 
conditions are described2,3. We used global self-reported cross-sectional data to 
characterise the factors associated with worsening psoriasis in the pandemic, focusing 
on the impact of anxiety and depression. 
Data from a cross-sectional survey (PsoProtectMe4) were extracted on 15th January 
2021. After excluding participants self-reporting COVID-19, the association between 
mental health and worsening psoriasis was assessed using a fully adjusted logistic 
regression model including covariates selected a priori as potentially influential on 
psoriasis severity and anxiety/depression. Participants scoring >3 in GAD-2 or PHQ-
2 defined a positive mental health screen5.  
4,043 people with psoriasis from 86 countries were included (Table 1). 1,728 (42.7%) 
reported worsening psoriasis in the pandemic. A greater proportion of those reporting 
worsening psoriasis had a positive mental health screen (814, 47.1%) compared to 
those without worsening psoriasis (562/1954, 28.8%). A greater proportion of females 
reported worsening psoriasis (1322/2684, 49.3%) compared with males (406/1354, 
30.0%).  
A fully adjusted regression model for worsening psoriasis estimated an odds ratio (OR) 
2.01 (95%CI 1.72-2.34) for those with a positive screen for anxiety or depression, 
compared to those without a positive screen (Figure 1). Associations were also 
observed for female gender (OR 1.82, 95%CI 1.56-2.13); obesity (OR 1.22, 95% CI 
1.09-1.36) and shielding (OR 1.18, 95%CI 1.03-1.35).  
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There were inverse associations with systemic therapy use (standard systemic OR 
0.69 [95%CI 0.56-0.86] and targeted therapy OR 0.49 [95%CI 0.38-0.64]). Of 1,541 
(38.1%) participants receiving systemic therapies for psoriasis, 284 (18.5%) reported 
non-adherence during the pandemic (Table 1). The commonest reason was concern 
regarding complications related to COVID-19 (n=217). Non-adherence was 
associated with worsening psoriasis (OR 2.90, 95%CI 2.31-3.63). A positive mental 
health screen was more common in those reporting non-adherence compared to those 
who were adherent (42.8% vs 32.4%).  
These data indicate a burden due to the COVID-19 pandemic in people with psoriasis; 
worsening psoriasis is common and is associated with poor mental health. We find 
that in the subset on systemic therapy, non-adherence is associated with worsening 
disease and is driven by concerns about immunosuppressant-related risks of COVID-
19. This is an important observation since current guidelines (informed by reassuring 
data on drug-related risks of severe COVID-196) recommend continuing 
immunosuppression in people without COVID-19 to maintain disease control7.  
Our findings parallel data from the general population indicating an increased mental 
health burden during the pandemic, particularly in women8. People with psoriasis - 
especially those with severe psoriasis, and women – have a high prevalence of anxiety 
and depression, and may thus be particularly vulnerable to the adverse impact of the 
pandemic on mental health9. Whilst men are known to be at greater risk of severe 
outcomes from COVID-19, our data suggest that women may be more susceptible to 
indirect excess morbidity – poor mental health and worsening skin disease – than men.   
The generalizability of results is limited given the self-selecting bias of our study 
population towards UK white women. Individuals non-adherent to treatment, with low 
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computer literacy or less anxiety may be disinclined to participate, which may 
introduce ascertainment bias.  
Our data underscore the importance of holistic models of care and indicate a need to 
provide access to psychological support. In those with worsening psoriasis, possible 
non-adherence should be explored. Evidence-based communication around 
medication-related COVID-19 risks and behavioural approaches for supporting 
adherence may help address fears, anxieties and confusion10. Attention given now to 
address this may mitigate a long-lasting detrimental impact of the pandemic on health 
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Fig. 1 title: Fully adjusted model for associations with worsening psoriasis.  
Fig. 1 legend: Odds ratios for associations with worsening psoriasis. 
Anxiety/depression is defined as those who screened positive for either anxiety or 




Table 1. Participant demographics and clinical characteristics stratified by disease 
state. 







  N=4,043 N=2,315 N=1,728   
Shielded  2,224 (55.1%) 1,240 (53.8%) 984 (56.9%)  0.045 
Advised to shield  742 (33.6%) 465 (37.5%) 277 (28.6%) <0.001 
Female gender 2,684 (66.4%) 1,362 (59.0%) 1,322 (76.5%) <0.001 
Age, mean (SD) 47.2 (15.1) 49.5 (15.3) 44.2 (14.3) <0.001 
White European ethnicity  3,016 (74.6%) 1,707 (73.7%) 1,309 (75.8%)  0.15 
BMI, mean (SD) 27.6 (6.0) 27.4 (5.8) 28.0 (6.3)  0.003 
Alcohol >14 units a week 495 (13.8%) 295 (15.0%) 200 (12.3%)  0.018 
Current smoker 559 (15.8%) 291 (15.0%) 268 (16.7%)  0.18 
Full time employed 1,929 (47.7%) 1,072 (46.3%) 857 (49.6%)  0.038 
Household number, mean (SD) 2.8 (1.8) 2.8 (1.7) 2.9 (1.9)  0.003 
Key worker 1,131 (28.1%) 595 (25.9%) 536 (31.1%) <0.001 
Psoriasis severity prior to COVID-19 
pandemic 
      <0.001 
   Clear 451 (12.0%) 299 (14.6%) 152 (8.9%)   
   Nearly clear 767 (20.4%) 463 (22.7%) 304 (17.7%)   
   Mild 989 (26.3%) 477 (23.3%) 512 (29.9%)   
   Moderate 892 (23.7%) 442 (21.6%) 450 (26.2%)   
   Moderate-severe 480 (12.8%) 273 (13.4%) 207 (12.1%)   
   Severe 180 (4.8%) 90 (4.4%) 90 (5.2%)   
Systemic therapy       <0.001 
   No Systemic Therapy 1,980 (56.2%) 938 (49.4%) 1,042 (64.2%)   
   Standard Systemic Therapy 560 (15.9%) 309 (16.3%) 251 (15.5%)   
   Targeted Therapy 981 (27.9%) 652 (34.3%) 329 (20.3%)   
Non adherent to systemic therapy 284 (18.5%) 114 (11.9%) 170 (29.6%) <0.001 
1 or more comorbidity  1,606 (39.7%) 908 (39.2%) 698 (40.4%)  0.45 
Anxiety 1,069 (30.1%) 408 (21.0%) 661 (41.0%) <0.001 
Depression 977 (27.5%) 392 (20.1%) 585 (36.5%) <0.001 
Anxiety or Depression 1,376 (38.5%) 562 (28.8%) 814 (50.2%) <0.001 
Table 1. SD = standard deviation, BMI = body mass index. Targeted therapy was defined as anyone taking TNF 
inhibitors (adalimumab, certolizumab, etanercept, infliximab), IL-17 inhibitors (ixekizumab, secukinumab, 
brodalumab), IL-23 inhibitors (guselkumab, risankizumab, ustekinumab) or apremilast. Standard systemic 
therapy was defined as anyone taking acitretin, ciclosporin, or methotrexate and not taking a targeted therapy. 
 
 
 
